All Trials

Phase 1b Study of Olaparib and Estradiol in Advanced ER+ Breast Cancer (PHOEBE)

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: This trial enrolls post-menopausal women with endocrine-resistant, advanced or recurrent ER-positive, HER2-negative breast cancer who have had at least one prior endocrine therapy in the advanced setting, testing olaparib (a PARP inhibitor that targets DNA repair defects) in combination with 17b-estradiol followed by 17b-estradiol alone.

ClinicalTrials.gov ID: NCT05900895

A Phase Ib/III, Open-label, Randomised Study of Capivasertib Plus CDK4/6 Inhibitors and Fulvestrant Versus CDK4/6 Inhibitors and Fulvestrant in Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative Locally Advanced, Unresectable or Metastatic Breast Cancer (CAPItello-292)

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: This trial enrolls adults with hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer who are candidates for fulvestrant and a CDK4/6 inhibitor, and randomizes them to receive either standard therapy (CDK4/6 inhibitor plus fulvestrant) or the addition of capivasertib, an oral AKT inhibitor targeting the PI3K/AKT pathway. Prior use of AKT/PI3K/mTOR inhibitors or CDK4/6 inhibitors in the advanced/metastatic setting are excluded.

ClinicalTrials.gov ID: NCT04862663

Phase II Trial of Palbociclib and Pembrolizumab in Central Nervous System Metastases

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Adults with progressive, measurable CNS metastases from solid tumors and CDK pathway alterations (Cohort 1) receive palbociclib, a selective CDK4/6 inhibitor, while patients with breast cancer brain metastases (Cohort 2) receive palbociclib plus pembrolizumab, an anti–PD-1 immunotherapy. Prior CNS-directed therapy is allowed; key exclusions include prior CDK4/6 inhibitor use, leptomeningeal disease (Cohort 1), and active autoimmune disease (Cohort 2).

ClinicalTrials.gov ID: NCT02896335

A Pilot Study of Sequential ("First Strike, Second Strike") Therapies, Modeled on Evolutionary Dynamics of Anthropocene Extinctions, for Hormone Positive Metastatic Breast Cancer

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: This trial enrolls adult women with hormone receptor-positive, HER2-negative metastatic breast cancer who have progressed after prior endocrine therapy, using a sequential regimen of standard chemotherapy (cyclophosphamide, docetaxel, GM-CSF), followed by either sacituzumab govitecan (Trop-2 antibody-drug conjugate) or trastuzumab deruxtecan (HER2 antibody-drug conjugate), then capecitabine, and finally fulvestrant plus a CDK4/6 inhibitor. Prior fulvestrant or active CNS metastases are exclusion criteria.

ClinicalTrials.gov ID: NCT06409390

A Phase 2 Study of Palliative Radiation in Combination with Pembrolizumab in Subjects with Unresectable Metastatic Stage IV Breast Cancer: Twisted Pink

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: This trial enrolls adult women with unresectable metastatic stage IV breast cancer who have progressed on at least two prior lines of standard therapy, including appropriate agents for their cancer subtype. Participants receive palliative stereotactic body radiation therapy (SBRT) combined with pembrolizumab, a PD-1 inhibitor immunotherapy.

ClinicalTrials.gov ID: NCT04990921

Phase II Study of Pembrolizumab and Ablative Radiotherapy With or Without Olaparib in Metastatic Triple-Negative or Hormone-Receptor Positive/Her2 Negative Breast Cancers : Initial Test Cohorts of a Platform Trial to Sequentially Investigate Immunotherapy Combinations for the Augmentation of Immune Responses

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: This trial enrolls adult women with metastatic triple-negative or ER-positive/HER2-negative breast cancer, including those who have progressed after prior immune checkpoint inhibitor therapy or are PD-L1 negative, to evaluate pembrolizumab (anti-PD-1 antibody) plus stereotactic ablative radiotherapy, with or without olaparib (PARP inhibitor), for systemic immune and tumor response.

ClinicalTrials.gov ID: NCT04683679

An Open-Label Phase II Trial of Neratinib Plus Capecitabine in Subjects with HER2-Negative Metastatic Breast Cancer with Brain Metastases and Abnormally Active HER2 Signaling

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: This trial enrolls adults with HER2-negative metastatic breast cancer and brain metastases whose tumors have abnormally active HER2 signaling (per CELsignia test), including both ER-positive and triple-negative subtypes, and treats them with the investigational HER2 pathway inhibitor neratinib plus capecitabine. Eligible patients must have appropriate prior treatment and be able to undergo biopsy and systemic therapy.

ClinicalTrials.gov ID: NCT04965064

An Open-label Multicenter Phase 1b-2 Study of Elacestrant in Combination With Abemaciclib in Women and Men With Brain Metastasis From Estrogen Receptor Positive, HER-2 Negative Breast Cancer

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: This trial enrolls adults with ER-positive, HER2-negative breast cancer and active, measurable brain metastases who have progressed on prior endocrine therapy (excluding prior abemaciclib in the metastatic setting), testing oral elacestrant (a selective estrogen receptor degrader) in combination with abemaciclib (a CDK4/6 inhibitor). The study excludes patients with leptomeningeal disease, imminent visceral crisis, or prior metastatic abemaciclib exposure.

ClinicalTrials.gov ID: NCT05386108

A Phase 1/2, Open-label, Multicenter, Dose-escalation, and Dose-Optimization Study to Evaluate the Safety, Tolerability, and Activity of EIK1004 (IMP1707) as Monotherapy in Participants With Advanced Solid Tumors

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

TrialFetch AI summary: This trial enrolls adults with advanced HRR-mutated solid tumors—including previously treated breast, ovarian, fallopian tube, primary peritoneal, castration-resistant prostate, or pancreatic cancers—who may have had limited prior PARP inhibitor exposure and CNS metastases if stable. Patients receive EIK1004 (IMP1707), a highly selective CNS-penetrant PARP1 inhibitor, as oral monotherapy.

ClinicalTrials.gov ID: NCT06907043

Stereotactic Body Radiation Therapy (SBRT) to Extend the Benefit of Systemic Therapy in Patients With Solitary Disease Progression

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: This trial enrolls adults with metastatic breast cancer (ER+/HER2- or any HER2+) who have had at least 6 months of response to systemic therapy and now show a solitary progressing metastasis; patients will receive SBRT to the progressive lesion while continuing their current systemic therapy. SBRT is delivered to the single progressing site with the intent to prolong systemic disease control.

ClinicalTrials.gov ID: NCT05534438